What was Aspen Neuroscience, Inc.’s price range in the past 12 months?
Aspen Neuroscience, Inc. lowest stock price was $11.60 and its highest was $14.90 in the past 12 months.
What is Aspen Neuroscience, Inc.’s market cap?
Aspen Neuroscience, Inc.’s market cap is $432.98M.
When is Aspen Neuroscience, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Aspen Neuroscience, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Aspen Neuroscience, Inc. pay dividends?
Aspen Neuroscience, Inc. does not currently pay dividends.
What is Aspen Neuroscience, Inc.’s EPS estimate?
Aspen Neuroscience, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Neuroscience, Inc. have?
Aspen Neuroscience, Inc. has 29,078,600 shares outstanding.
Which hedge fund is a major shareholder of Aspen Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ASPE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.